



Effective Date: 10/01/2019
 Last P&T Approval/Version: 04/2022
 Next Review Due By: 04/2023
 Policy Number: C21453-A

Anticonvulsants – IL Medicaid Only

PRODUCTS AFFECTED

Aptiom (Eslicarbazepine Acetate Tab); Banzel (Rufinamide Susp); Banzel (Rufinamide Tab); Briviact (Brivaracetam Oral Soln); Briviact (Brivaracetam Tab); carBAMazepine (Carbamazepine Cap ER 12HR); Carbatrol (Carbamazepine Cap ER 12HR); Celontin (Methsuximide Cap); cloBAZam (Clobazam Suspension); cloBAZam (Clobazam Tab); clonazePAM (Clonazepam Orally Disintegrating); Depakote (Divalproex Sodium Tab ER 24 HR); Depakote (Divalproex Sodium Cap Delayed Release Sprinkle); Depakote (Divalproex Sodium Tab Delayed Release); Diacomit (Stiripentol Cap); Diacomit (Stiripentol Packet); Dilantin (Phenytoin Sodium Extended); Dilantin (Phenytoin Chew Tab); Dilantin (Phenytoin Susp); Elepsia (Levetiracetam Tab ER 24HR); Epidiolex (Cannabidiol Soln); Eprontia (Topiramate Oral Soln); Felbamate (Felbamate Susp); Felbamate (Felbamate Tab); Felbatol (Felbamate Susp); Felbatol (Felbamate Tab); Fintepla (Fenfluramine HCl Oral); Fycompa (Perampanel Susp); Fycompa (Perampanel Tab); Gabitril (Tiagabine HCl Tab); Keppra (Levetiracetam Oral Soln); Keppra (Levetiracetam Tab); Keppra (Levetiracetam Tab ER 24HR); Klonopin (Clonazepam Tab); Lacosamide (Lacosamide Tab); LaMICtal (Lamotrigine Tab Chewable Dispersible); LaMICtal (Lamotrigine Tab Disint); LaMICtal (Lamotrigine Orally Disintegrating); LaMICtal (Lamotrigine Tab); LaMICtal (Lamotrigine Tab ER 24HR); lamoTRigine (Lamotrigine Tab ER 24HR); lamoTRigine (Lamotrigine Tab Disint); lamoTRigine (Lamotrigine Tab); lamoTRigine (Lamotrigine Orally Disintegrating); Mysoline (Primidone Tab); Nayzilam (Midazolam Nasal Spray); Neurontin (Gabapentin Cap); Neurontin (Gabapentin Oral Soln); Neurontin (Gabapentin Tab); Onfi (Clobazam Suspension); Onfi (Clobazam Tab); Oxtellar (Oxcarbazepine Tab ER 24HR); Phenytek (Phenytoin Sodium Extended); Qudexy (Topiramate Cap ER 24HR Sprinkle); Rufinamide (Rufinamide Susp); Rufinamide (Rufinamide Tab); Sabril (Vigabatrin Powd Pack); Sabril (Vigabatrin Tab); Spritam (Levetiracetam Tab Disintegrating Soluble); Subvenite (Lamotrigine Tab); Sympazan (Clobazam Oral Film); TEGretol (Carbamazepine Susp); TEGretol (Carbamazepine Tab); TEGretol-XR (Carbamazepine Tab ER 12HR); tiaGABine (Tiagabine HCl Tab); Topamax (Topiramate Sprinkle Cap); Topamax (Topiramate Tab); Topiramate (Topiramate Cap ER 24HR Sprinkle); Trileptal (Oxcarbazepine Susp); Trileptal (Oxcarbazepine Tab); Trokendi (Topiramate Cap ER 24HR); Valtoco (Diazepam Nasal Spray); Vigabatrin (Vigabatrin Powd Pack); Vigabatrin (Vigabatrin Tab); Vigadrone (Vigabatrin Powd Pack); Vimpat (Lacosamide Oral Solution); Vimpat (Lacosamide Tab); Zarontin (Ethosuximide Cap); Zarontin (Ethosuximide Soln)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines

Drug and Biologic Coverage Criteria

Documentation Requirements:

Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive

DIAGNOSIS:

Epilepsy or Seizure disorder

REQUIRED MEDICAL INFORMATION:

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review

- A. Epilepsy or Seizure disorder
 - 1. Documentation that member has a diagnosis of diagnosis of epilepsy or seizure disorder.
- B. ALL OTHER INDICATIONS
 - 1. Review per IL Medicaid Medical Necessity Review.

CONTINUATION OF THERAPY:

- A. Epilepsy or Seizure disorder
 - 1. Documentation that member has a diagnosis of diagnosis of epilepsy or seizure disorder.
- B. ALL OTHER INDICATIONS
 - 1. Review per IL Medicaid Medical Necessity Review.

DURATION OF APPROVAL:

12 months

PRESCRIBER REQUIREMENTS:

None

AGE RESTRICTIONS:

N/A

QUANTITY:

Quantity limit per Illinois Medical Preferred drug listing.

PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

The recommendation is that intranasal medications in this policy will be for pharmacy benefit coverage and patient self-administered.

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Oral, Intranasal

DRUG CLASS:

Anticonvulsants

FDA-APPROVED USES:

COMPENDIAL APPROVED OFF-LABELED USES:

None

APPENDIX

APPENDIX:

G40 Epilepsy and recurrent seizures

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:

All other uses of agents listed in this policy are considered experimental/investigational and therefore, will follow Molina’s Off- Label policy.

OTHER SPECIAL CONSIDERATIONS:

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCPCS CODE	DESCRIPTION
NA	

AVAILABLE DOSAGE FORMS:

- | | | |
|-----------------------|-----------------------|------------------------|
| Aptiom TABS 200MG | Briviact TABS 25MG | Carbatrol CP12 200MG |
| Aptiom TABS 400MG | Briviact TABS 50MG | Carbatrol CP12 300MG |
| Aptiom TABS 600MG | Briviact TABS 75MG | Celontin CAPS 300MG |
| Aptiom TABS 800MG | carBAMazepine ER CP12 | cloBAZam SUSP 2.5MG/ML |
| Banzel SUSP 40MG/ML | 100MG | cloBAZam TABS 10MG |
| Banzel TABS 200MG | carBAMazepine ER CP12 | cloBAZam TABS 20MG |
| Banzel TABS 400MG | 200MG | clonazePAM TBDP |
| Briviact SOLN 10MG/ML | carBAMazepine ER CP12 | 0.125MG |
| Briviact TABS 100MG | 300MG | clonazePAM TBDP 0.25MG |
| Briviact TABS 10MG | Carbatrol CP12 100MG | clonazePAM TBDP 0.5MG |

Drug and Biologic Coverage Criteria

clonazepam TBP 1MG	Lacosamide TABS 50MG	MG & 14x100 MG
clonazepam TBP 2MG	LaMICtal CHEW 25MG	lamoTRlgine Starter Kit-Blue
Depakote ER TB24 250MG	LaMICtal CHEW 5MG	KIT 35 x 25MG
Depakote ER TB24 500MG	LaMICtal ODT KIT 21 x 25	lamoTRlgine Starter Kit-
Depakote Sprinkles CSDR	MG & 7 x 50 MG	Green KIT 84 x 25 MG
125MG	LaMICtal ODT KIT 25 & 50	& 14x100 MG
Depakote TBEC 125MG	& 100MG	lamoTRlgine Starter Kit-
Depakote TBEC 250MG	LaMICtal ODT KIT 42 x 50	Orange KIT 42 x 25 MG & 7
Depakote TBEC 500MG	MG & 14x100 MG	x 100 MG
Diacomit CAPS 250MG	LaMICtal ODT TBP	lamoTRlgine TBP 100MG
Diacomit CAPS 500MG	100MG	lamoTRlgine TBP 200MG
Diacomit PACK 250MG	LaMICtal ODT TBP	lamoTRlgine TBP 25MG
Diacomit PACK 500MG	200MG	lamoTRlgine TBP 50MG
Dilantin CAPS 100MG	LaMICtal ODT TBP 25MG	Mysoline TABS 250MG
Dilantin CAPS 30MG	LaMICtal ODT TBP 50MG	Mysoline TABS 50MG
Dilantin Infatabs CHEW	LaMICtal Starter KIT 35 x	Nayzilam SOLN 5MG/0.1ML
50MG	25MG	Neurontin CAPS 100MG
Dilantin SUSP 125MG/5ML	LaMICtal Starter KIT 42 x 25	Neurontin CAPS 300MG
Elepsia XR TB24 1000MG	MG & 7 x 100 MG	Neurontin CAPS 400MG
Elepsia XR TB24 1500MG	LaMICtal Starter KIT 84 x 25	Neurontin SOLN
Epidiolex SOLN 100MG/ML	MG & 14x100 MG	250MG/5ML
Eprontia SOLN 25MG/ML	LaMICtal TABS 100MG	Neurontin TABS 600MG
Felbamate SUSP	LaMICtal TABS 150MG	Neurontin TABS 800MG
600MG/5ML	LaMICtal TABS 200MG	Onfi SUSP 2.5MG/ML
Felbamate TABS 400MG	LaMICtal TABS 25MG	Onfi TABS 10MG
Felbamate TABS 600MG	LaMICtal XR KIT 21 x 25	Onfi TABS 20MG
Felbatol SUSP 600MG/5ML	MG & 7 x 50 MG	Oxtellar XR TB24 150MG
Felbatol TABS 400MG	LaMICtal XR KIT 25 & 50 &	Oxtellar XR TB24 300MG
Felbatol TABS 600MG	100MG	Oxtellar XR TB24 600MG
Fintepla SOLN 2.2MG/ML	LaMICtal XR KIT 50 & 100 &	Phenytek CAPS 200MG
Fycompa SUSP 0.5MG/ML	200MG	Phenytek CAPS 300MG
Fycompa TABS 10MG	LaMICtal XR TB24 100MG	Qudexy XR CS24 100MG
Fycompa TABS 12MG	LaMICtal XR TB24 200MG	Qudexy XR CS24 150MG
Fycompa TABS 2MG	LaMICtal XR TB24 250MG	Qudexy XR CS24 200MG
Fycompa TABS 4MG	LaMICtal XR TB24 25MG	Qudexy XR CS24 25MG
Fycompa TABS 6MG	LaMICtal XR TB24 300MG	Qudexy XR CS24 50MG
Fycompa TABS 8MG	LaMICtal XR TB24 50MG	Rufinamide SUSP 40MG/ML
Gabitril TABS 12MG	lamoTRlgine ER TB24	Rufinamide TABS 200MG
Gabitril TABS 16MG	100MG	Rufinamide TABS 400MG
Gabitril TABS 2MG	lamoTRlgine ER TB24	Sabril PACK 500MG
Gabitril TABS 4MG	200MG	Sabril TABS 500MG
Keppra SOLN 100MG/ML	lamoTRlgine ER TB24	Spritam TB3D 1000MG
Keppra TABS 1000MG	250MG	Spritam TB3D 250MG
Keppra TABS 250MG	lamoTRlgine ER TB24	Spritam TB3D 500MG
Keppra TABS 500MG	25MG	Spritam TB3D 750MG
Keppra TABS 750MG	lamoTRlgine ER TB24	Subvenite Starter Kit-Blue
Keppra XR TB24 500MG	300MG	KIT 35 x 25MG
Keppra XR TB24 750MG	lamoTRlgine ER TB24	Subvenite Starter Kit-Green
KlonoPIN TABS 0.5MG	50MG	KIT 84 x 25 MG & 14x100
KlonoPIN TABS 1MG	lamoTRlgine KIT 21 x 25	MG
KlonoPIN TABS 2MG	MG & 7 x 50 MG	Subvenite Starter Kit-Orange
Lacosamide TABS 100MG	lamoTRlgine KIT 25 & 50 &	KIT 42 x 25 MG & 7 x 100
Lacosamide TABS 150MG	100MG	MG
Lacosamide TABS 200MG	lamoTRlgine KIT 42 x 50	Sympazan FILM 10MG

Drug and Biologic Coverage Criteria

Sympazan FILM 20MG	Topamax TABS 50MG	10MG/0.1ML
Sympazan FILM 5MG	Topiramate ER CS24	Valtoco 15 MG Dose LQPK
TEGretol SUSP 100MG/5ML	100MG	7.5MG/0.1ML
TEGretol TABS 200MG	Topiramate ER CS24	Valtoco 20 MG Dose LQPK
TEGretol-XR TB12 100MG	150MG	10MG/0.1ML
TEGretol-XR TB12 200MG	Topiramate ER CS24	Valtoco 5 MG Dose LIQD
TEGretol-XR TB12 400MG	200MG	5MG/0.1ML
tiaGABine HCl TABS 12MG	Topiramate ER CS24 25MG	Vigabatrin PACK 500MG
tiaGABine HCl TABS 16MG	Topiramate ER CS24 50MG	Vigabatrin TABS 500MG
tiaGABine HCl TABS 2MG	Trileptal SUSP 300MG/5ML	Vigadrone PACK 500MG
tiaGABine HCl TABS 4MG	Trileptal TABS 150MG	Vimpat SOLN 10MG/ML
Topamax Sprinkle CPSP	Trileptal TABS 300MG	Vimpat TABS 100MG
15MG	Trileptal TABS 600MG	Vimpat TABS 150MG
Topamax Sprinkle CPSP	Trokendi XR CP24 100MG	Vimpat TABS 200MG
25MG	Trokendi XR CP24 200MG	Vimpat TABS 50MG
Topamax TABS 100MG	Trokendi XR CP24 25MG	Zarontin CAPS 250MG
Topamax TABS 200MG	Trokendi XR CP24 50MG	Zarontin SOLN 250MG/5M
Topamax TABS 25MG	Valtoco 10 MG Dose LIQD	

REFERENCES

1. Illinois Medicaid Preferred Drug List, Effective April 1, 2022
2. <https://ilga.gov/legislation/publicacts/101/PDF/101-0209.pdf>

SUMMARY OF REVIEW/REVISIONS	DATE
ANNUAL REVIEW COMPLETED- No coverage criteria changes with this annual review.	Q2/2022
Updated reference to Medical Necessity and deleted Global Clinical Exception Policy	7/2022